Description
This completely updated 2nd edition to Kalorama’s popular 2003 study focuses on the market applications of current and advanced drug delivery technology to the development of new and modified pharmaceutical products in the United States. Taking a strategic view of the various therapeutic areas on which drug delivery is anticipated to have its greatest impact, the report considers the options that the current technologies present, the progress that is being made in these fields, and the reception these new products are likely to experience in the marketplace.
In particular, the 400-page study examines the market potential of modified-delivery therapeutics in the following therapeutic categories:
- Cardiovascular Diseases (including Coronary Stents),
- Cancer,
- Central Nervous System (CNS) Applications,
- Diabetes,
- Fertility Control and Women’s Health,
- Infectious Diseases, and
- Pulmonary Diseases (including upper respiratory conditions)
This report discusses the economic aspects of certain advanced drug delivery technologies and applications, and their impacts on formularies, insurers and patients. In addition to the market analysis and a thorough review of available technologies and those in development, the report extensively profiles the leading delivery technology companies, noting their portfolios, development pipelines, financial performance, and strategic partnerships.
Market analysis for this report considers the markets modified drug delivery products only in the United States. The focus of the report is on the application of advanced drug delivery technology in the improvements of existing pharmaceuticals and the facilitation of the delivery and commercialization of new therapeutics emerging from the biotechnology and biopharmaceutical industries.
The analysis presented in this report is based on data from a combination of company, government, industrial, institutional and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including experts in drug delivery technology, as well as medicinal chemists, research scientists, and business development and marketing managers engaged in the field.
Table of Contents
CHAPTER ONE: Executive Summary
- Background
- Scope and Methodology
- Technology and Market Opportunities
- Polymers and Biomaterials
- Oral Drug Delivery Devices
- Pulmonary Drug Delivery
- Drug Eluting Stent Technology
- Percutaneous Drug Delivery Technology
- Ophthalmic Drug Delivery
- Colloidal Drug Delivery Technologies
- Site/Organ Specific Drug Delivery
- Needle-Free Drug Delivery Technology
- Size and Growth of Market
CHAPTER TWO: Drug Delivery Technologies
- Pharmacodynamics and Drug Delivery
- Small Organic Molecules
- Pharmaceutical Proteins
- Vaccines
- Genes and Antisense Drugs
- Polymers and Biomaterials
- Non-Absorbable Polymers
- Polyamine Analogs
- Magnapore Polymers
- Natural Biopolymers
- Intelligent Polymers
- Oral Drug Delivery Devices
- Extended-Release Technology
- Delayed-Release Technology
- Immediate-Dissolution Technology
- Pulmonary Drug Delivery
- Drug Eluting Stent Technology
- Percutaneous Drug Delivery Technology
- Intranasal Delivery
- Iontophoresis
- Phonophoresis
- Electroporation
- Ophthalmic Drug Delivery
- Colloidal Drug Delivery Technologies
- Site/Organ Specific Drug Delivery
- Implantable Drug Delivery Systems
- Needle-Free Drug Delivery Technology
- Microneedle Technology
- Nanobiotechnology
CHAPTER THREE: Drug Delivery Applications and Markets
- Background
- Cardiovascular Diseases
- Technology Applications
- Market Assessment
- Cancer
- Technology Applications
- Market Assessment
- Central Nervous System (CNS) Applications
- Technology Applications
- Market Assessment
- Diabetes
- Technology Applications
- Market Assessment
- Fertility Control and Women’s Health
- Technology Applications
- Market Assessment
- Infectious Diseases
- Technology Applications
- Market Assessment
- Pulmonary Diseases
- Technology Applications
- Market Assessment
CHAPTER FOUR: Company Profiles
- Overview
- Abbott Vascular Devices Division of Abbott Laboratories
- Alkermes, Inc.
- Andrx Corporation
- Bioject Medical Technologies
- Biovail Corporation
- Boston Scientific
- Cima Labs Inc., A Cephalon Company
- Cordis Corporation A Johnson & Johnson Company
- CyDex, Inc.
- DelSite Biotechnologies
- Durect Corporation
- Elan Corporation plc
- Enzon Pharmaceuticals, Inc.
- Genzyme General
- Guidant Corporation
- Guilford Pharmaceuticals Inc.
- Medtronic, Inc.
- Nastech Pharmaceutical Company Inc.
- Nektar Therapeutics, Inc.
- Skyepharma plc
CHAPTER FIVE: Conclusions and Strategic Implications
- First Conclusion
- Implications:
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
- Seventh Conclusion
- Implications:
Appendix A: Glossary
Appendix B: List of Companies
List of Exhibits
CHAPTER ONE: Executive Summary
- Table 1-1: Estimated U.S. Market Potential for Delivery-Modified Therapeutics 2004-2014
- Table 1-2: Estimated United States Market Potential for Delivery-Modified Therapeutics by Application Area (Cardiovascular, Cancer, CNS, Diabetes, Women’s Health, Infectious Disease, Pulmonary) 2004-2014
- Figure 1-1: Trending in the Estimated United States Market Potential for Delivery-Modified Therapeutics by Therapeutic Area 2004-2014
CHAPTER TWO: Drug Delivery Technologies
- Table 2-1: Key Companies Active in Drug Delivery Technology and Products
- Table 2-2: Commonly Used Polymeric Materials for Controlled Drug Release Systems
- Table 2-3: Key Companies Active in Pulmonary Drug Delivery Technology by Application Area/Type of Participation (Diabetes, Pain, Nicotine, OEM Provider, Co-Developer, Asthma, COPD, Cystic Fibrosis, Endocrinology, Reproductive/Hormones, Sleep Disorders, Growth Hormone Deficiency, Prostate Cancer)
- Table 2-4: Pharmaceutical Candidates for Drug-Eluting Stents
- Table 2-5: Companies Active in Drug-Eluting Stent Commercialization by Segment of Participation (Drugs, Coatings, Stents, Drug-Eluting Stents)
- Table 2-6: Phonophoresis/Cortisol Trial Results
Chapter Three: Drug Delivery Applications and Markets
- Table 3-1: Estimated U.S. Market Potential for Delivery Modified Therapeutics by Therapeutic Area (Cardiovascular, Cancer, CNS, Diabetes, Women’s Health, Infectious Disease, Pulmonary) 2004-2014
- Figure 3-1: Distribution of the Estimated United States Market Potential for Delivery-Modified Therapeutics by Therapeutic Area: 2004-2014
- Table 3-2: Currently Marketed Drug Delivery Modified Cardiovascular Products (Brand, Generic, Manufacturer, Application)
- Table 3-3: Pharmaceutical Candidates for Drug-Eluting Stents
- Table 3-4: Companies Active in Drug-Eluting Stent Commercialization by Segment of Participation (Drugs, Coatings, Stents, Drug-Eluting Stents)
- Figure 3-2: Trending in Historic and Forecast United States Coronary Revascularization Procedures: 1990 – 2014
- Table 3-5: Potential U.S. Market for Drug Delivery-Modified Cardiovascular
- Drugs and Drug-Eluting Stents 2004-2014
- Figure 3-3: Trending in the United States Market for Drug Eluting Stents and Modified Delivery Pharmaceuticals 2004-2014
- Figure 3-4: Trending in the Potential United States Market for Delivery All
- Modified Cardiovascular Drug Delivery Products: 2004-2014
- Table 3-6: Currently Marketed Drug Delivery Modified Cancer Therapy Products
- Table 3-7: Potential U.S. Market for Drug Delivery-Modified Cancer Therapeutics by Type (Cytotoxic, Hormone, Blood Restorative, Pain Management, Infection Control) 2004-2014
- Figure 3-6: Trending in the Potential United States Market for Drug Delivery-Modified Cancer Therapeutics: 2001 – 2010
- Table 3-8: Currently Marketed Drug Delivery Modified CNS Therapy Products
- Table 3-9: Potential United States Market for Drug Delivery-Modified CNS Therapeutics: 2004-2014
- Figure 3-7: Trending in the Potential United States Market for Delivery Modified CNS Therapeutics: 2004-2014
- Table 3-10: Currently Marketed Drug Delivery-Modified Diabetes Therapeutics
- Table 3-11: Potential U.S. Market for Drug Delivery-Modified Diabetes
- Therapeutics by Type (Insulin, Oral Hypoglycemics) 2004-2014
- Figure 3-8: Trending in the Potential United States Market for Delivery
- Modified Diabetes Therapeutics: 2004-2014
- Table 3-12: Currently Marketed Drug Delivery-Modified Fertility and
- Women’s Health Products
- Table 3-13: Potential United States Market for Drug Delivery-Modified
- Fertility Control and Women’s Health Drugs: 2004-2014
- Figure 3-9: Trending in the Potential United States Market for Delivery-
- Modified Fertility Control and Women’s Health Drugs 2004-2014
- Table 3-12: Currently Marketed Drug Delivery-Modified Infectious Disease Drugs
- Table 3-13: Potential United States Market for Drug Delivery-Modified Infectious Disease Therapeutics 2004-2014
- Figure 3-10: Trending in the Potential United States Market for Delivery Modified Infectious Disease Therapeutics: 2004-2014
- Table 3-14: Currently Marketed Drug Delivery-Modified Pulmonary Disease Therapeutics
- Table 3-15: Potential United States Market for Drug Delivery-Modified Pulmonary Disease Therapeutics 2004 – 2014
- Figure 3-11: Trending in the Potential United States Market for Delivery Modified Pulmonary Disease Therapeutics 2004-2014
